Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D F Bajorin

Showing results (91-100 of 97) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 97 results.
The Journal of Urology|April 1, 2021
Utility of Routine Preoperative <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy. ReplyS Dason, N C Wong, T F Donahue, et al.
ESMO Open|June 6, 2025
Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinomaM Sternschuss, N Toumbacaris, J P Das, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2025
Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumorsR S Matulewicz, F Baky, N Liso, et al.
Clinical Genitourinary Cancer|July 5, 2014
Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial designG R Pond, J Bellmunt, J E Rosenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274M D Galsky, J E Gschwend, M I Milowsky, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-upY Fradet, J Bellmunt, D J Vaughn, et al.
Urologic Oncology|June 4, 2018
Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma."M Y Teo, R M Bambury, E C Zabor, et al.
Pageof 10

Showing results (91-100 of 97) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 97 results.
The Journal of Urology|April 1, 2021
Utility of Routine Preoperative <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography in Identifying Pathological Lymph Node Metastases at Radical Cystectomy. ReplyS Dason, N C Wong, T F Donahue, et al.
ESMO Open|June 6, 2025
Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinomaM Sternschuss, N Toumbacaris, J P Das, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 12, 2025
Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumorsR S Matulewicz, F Baky, N Liso, et al.
Clinical Genitourinary Cancer|July 5, 2014
Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial designG R Pond, J Bellmunt, J E Rosenberg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274M D Galsky, J E Gschwend, M I Milowsky, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2019
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-upY Fradet, J Bellmunt, D J Vaughn, et al.
Urologic Oncology|June 4, 2018
Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma."M Y Teo, R M Bambury, E C Zabor, et al.
Pageof 10